| scholarly article | Q13442814 |
| P819 | ADS bibcode | 2003PNAS..100.4498G |
| P356 | DOI | 10.1073/PNAS.0831128100 |
| P8608 | Fatcat ID | release_hg7yg4b3cfgd5hbn7n3alcg3ia |
| P932 | PMC publication ID | 153584 |
| P698 | PubMed publication ID | 12676990 |
| P5875 | ResearchGate publication ID | 10820872 |
| P2093 | author name string | William C Olson | |
| Paul J Maddon | |||
| Jason P Gardner | |||
| Robert J Durso | |||
| Tatjana Dragic | |||
| Gerald P Donovan | |||
| Robert R Arrigale | |||
| P2860 | cites work | Binding of hepatitis C virus to CD81 | Q22004178 |
| A dendritic cell-specific intercellular adhesion molecule 3-grabbing nonintegrin (DC-SIGN)-related protein is highly expressed on human liver sinusoidal endothelial cells and promotes HIV-1 infection | Q24290940 | ||
| The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus | Q24307963 | ||
| cis Expression of DC-SIGN allows for more efficient entry of human and simian immunodeficiency viruses via CD4 and a coreceptor | Q24530658 | ||
| Functional evaluation of DC-SIGN monoclonal antibodies reveals DC-SIGN interactions with ICAM-3 do not promote human immunodeficiency virus type 1 transmission | Q24537674 | ||
| C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans | Q24537682 | ||
| Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR | Q24551041 | ||
| DC-SIGNR, a DC-SIGN homologue expressed in endothelial cells, binds to human and simian immunodeficiency viruses and activates infection in trans | Q24601035 | ||
| Functional analysis of cell surface-expressed hepatitis C virus E2 glycoprotein | Q27469721 | ||
| Formation of native hepatitis C virus glycoprotein complexes. | Q27480776 | ||
| Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor | Q27485871 | ||
| Detection of hepatitis C virus RNA by a combined reverse transcription-polymerase chain reaction assay | Q27487862 | ||
| Structural basis for selective recognition of oligosaccharides by DC-SIGN and DC-SIGNR | Q27636713 | ||
| Hepatitis C virus infection | Q27861002 | ||
| DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells | Q28138968 | ||
| Local control of the immune response in the liver | Q28144211 | ||
| Identification of DC-SIGN, a novel dendritic cell-specific ICAM-3 receptor that supports primary immune responses | Q28616569 | ||
| Folding, assembly and subcellular localization of hepatitis C virus glycoproteins | Q33791619 | ||
| The role of the hepatitis C virus glycoproteins in infection. | Q33860756 | ||
| The lymphoid system in hepatitis C virus infection: autoimmunity, mixed cryoglobulinemia, and Overt B-cell malignancy | Q33914312 | ||
| A novel mechanism of carbohydrate recognition by the C-type lectins DC-SIGN and DC-SIGNR. Subunit organization and binding to multivalent ligands | Q33949153 | ||
| Expression of DC-SIGN by dendritic cells of intestinal and genital mucosae in humans and rhesus macaques | Q34331629 | ||
| Dissecting virus entry via endocytosis | Q34697258 | ||
| Liver endothelium mediates the hepatocyte's uptake of ceruloplasmin | Q36214821 | ||
| HIV-1 membrane fusion: targets of opportunity | Q36366904 | ||
| Neutralizing monoclonal antibodies block human immunodeficiency virus type 1 infection of dendritic cells and transmission to T cells. | Q39583017 | ||
| Quantitative expression and virus transmission analysis of DC-SIGN on monocyte-derived dendritic cells | Q39684486 | ||
| Human immunodeficiency virus envelope (gp120) binding to DC-SIGN and primary dendritic cells is carbohydrate dependent but does not involve 2G12 or cyanovirin binding sites: implications for structural analyses of gp120-DC-SIGN binding | Q39685547 | ||
| Dendritic cell (DC)-specific intercellular adhesion molecule 3 (ICAM-3)-grabbing nonintegrin (DC-SIGN, CD209), a C-type surface lectin in human DCs, is a receptor for Leishmania amastigotes. | Q40578638 | ||
| Low level or absent in vivo replication of hepatitis C virus and hepatitis G virus/GB virus C in peripheral blood mononuclear cells | Q42987718 | ||
| Impaired allostimulatory capacity of peripheral blood dendritic cells recovered from hepatitis C virus-infected individuals | Q42993342 | ||
| Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection | Q43001795 | ||
| Dendritic cell susceptibility to hepatitis C virus genotype 1 infection | Q43037754 | ||
| The dendritic cell-specific adhesion receptor DC-SIGN internalizes antigen for presentation to T cells | Q43891685 | ||
| Efficient presentation of exogenous antigen by liver endothelial cells to CD8+ T cells results in antigen-specific T-cell tolerance | Q44002901 | ||
| Endothelial cell-mediated uptake of a hepatitis B virus: a new concept of liver targeting of hepatotropic microorganisms | Q45735445 | ||
| Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection | Q45737458 | ||
| Effect of glycosylation on antibody function: implications for genetic engineering | Q46879419 | ||
| Human Cytomegalovirus Binding to DC-SIGN Is Required for Dendritic Cell Infection and Target Cell trans-Infection | Q57083074 | ||
| Identification of Different Binding Sites in the Dendritic Cell-specific Receptor DC-SIGN for Intercellular Adhesion Molecule 3 and HIV-1 | Q58620062 | ||
| DC-SIGN-mediated internalization of HIV is required for trans-enhancement of T cell infection | Q77589727 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | virus | Q808 |
| virology | Q7215 | ||
| hepatitis C | Q154869 | ||
| Hepatitis C virus | Q708693 | ||
| P304 | page(s) | 4498-503 | |
| P577 | publication date | 2003-04-15 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus | |
| P478 | volume | 100 |
| Q34335916 | A look behind closed doors: interaction of persistent viruses with dendritic cells |
| Q53627018 | All but the shortest polymorphic forms of the viral receptor DC-SIGNR assemble into stable homo- and heterotetramers. |
| Q34916120 | An overview of HCV molecular biology, replication and immune responses |
| Q27472672 | Analysis of a Highly Flexible Conformational Immunogenic Domain A in Hepatitis C Virus E2 |
| Q39912694 | Anti-CD81 antibodies can prevent a hepatitis C virus infection in vivo |
| Q34315915 | Barriers of hepatitis C virus interspecies transmission |
| Q27472768 | Basic residues in hypervariable region 1 of hepatitis C virus envelope glycoprotein e2 contribute to virus entry |
| Q57241788 | Blocking HCV entry as potential antiviral therapy |
| Q35546564 | Bovine viral diarrhea virus as a surrogate model of hepatitis C virus for the evaluation of antiviral agents |
| Q38290950 | Branched oligosaccharide structures on HBV prevent interaction with both DC-SIGN and L-SIGN. |
| Q42802871 | C-type lectin LSECtin interacts with DC-SIGNR and is involved in hepatitis C virus binding. |
| Q28263849 | C-type lectins L-SIGN and DC-SIGN capture and transmit infectious hepatitis C virus pseudotype particles |
| Q27480351 | CD81 Expression Is Important for the Permissiveness of Huh7 Cell Clones for Heterogeneous Hepatitis C Virus Infection |
| Q27486789 | CD81 Is a Central Regulator of Cellular Events Required for Hepatitis C Virus Infection of Human Hepatocytes |
| Q29614812 | CD81 is an entry coreceptor for hepatitis C virus |
| Q29619745 | CD81 is required for hepatitis C virus glycoprotein-mediated viral infection |
| Q42262704 | CD81 sequence and susceptibility to hepatitis C infection |
| Q27485659 | CD81-Dependent Binding of Hepatitis C Virus E1E2 Heterodimers |
| Q36385222 | Cell entry of hepatitis C virus |
| Q29619744 | Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus |
| Q56985358 | Characterization of peritoneal cells from cats with experimentally-induced feline infectious peritonitis (FIP) using RNA-seq |
| Q27473226 | Characterization of the Early Steps of Hepatitis C Virus Infection by Using Luciferase Reporter Viruses |
| Q33234572 | Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33. |
| Q37201846 | Cutting the gordian knot-development and biological relevance of hepatitis C virus cell culture systems |
| Q24673797 | DC-SIGN and CLEC-2 mediate human immunodeficiency virus type 1 capture by platelets |
| Q40213399 | DC-SIGN and DC-SIGNR interact with the glycoprotein of Marburg virus and the S protein of severe acute respiratory syndrome coronavirus |
| Q28279039 | DC-SIGN and L-SIGN: the SIGNs for infection |
| Q38344672 | DC-SIGN binds to HIV-1 glycoprotein 120 in a distinct but overlapping fashion compared with ICAM-2 and ICAM-3. |
| Q38155234 | DC-SIGN, DC-SIGNR and LSECtin: C-type lectins for infection |
| Q28204447 | DC-SIGN: escape mechanism for pathogens |
| Q33624517 | De Novo modeling of Envelope 2 protein of HCV isolated from Pakistani patient and epitopes prediction for vaccine development |
| Q27010312 | Dendritic Cells in HIV-1 and HCV Infection: Can They Help Win the Battle? |
| Q37713961 | Determining the involvement and therapeutic implications of host cellular factors in hepatitis C virus cell-to-cell spread |
| Q40237799 | Development of global consensus sequence of HCV glycoproteins involved in viral entry |
| Q45927002 | Distinct kinetics and dynamics of cross-presentation in liver sinusoidal endothelial cells compared to dendritic cells. |
| Q27477625 | Diverse CD81 Proteins Support Hepatitis C Virus Infection |
| Q40530808 | Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner |
| Q36927297 | ERK signaling is triggered by hepatitis C virus E2 protein through DC-SIGN |
| Q48008012 | Evaluation of the role of the endocytic receptor L-SIGN for cytoadhesion of Plasmodium falciparum-infected erythrocytes |
| Q27477777 | Expression of DC-SIGN and DC-SIGNR on Human Sinusoidal Endothelium |
| Q42991985 | Genetic heterogeneity of the hypervariable region I of Hepatitis C virus and lymphoproliferative disorders |
| Q42132224 | Geometry and adhesion of extracellular domains of DC-SIGNR neck length variants analyzed by force-distance measurements |
| Q42426768 | Gumming up the works: DNA polymers as HCV entry inhibitors |
| Q40589291 | HCV E2 glycoprotein: mutagenesis of N-linked glycosylation sites and its effects on E2 expression and processing |
| Q36874176 | HCV Envelope protein 2 sequence comparison of Pakistani isolate and In-silico prediction of conserved epitopes for vaccine development |
| Q43010859 | HCV and HIV binding lectin, DC-SIGNR, is expressed at all stages of HCV induced liver disease. |
| Q30438047 | HCV infection of the transplanted liver: changing CD81 and HVR1 variants immediately after liver transplantation |
| Q27473290 | Hepatitis C Virus Entry Depends on Clathrin-Mediated Endocytosis |
| Q90523108 | Hepatitis C Virus Entry: An Intriguingly Complex and Highly Regulated Process |
| Q27481012 | Hepatitis C Virus Envelope Glycoprotein E2 Glycans Modulate Entry, CD81 Binding, and Neutralization |
| Q27489242 | Hepatitis C Virus entry: the early steps in the viral replication cycle |
| Q35917417 | Hepatitis C drug discovery: in vitro and in vivo systems and drugs in the pipeline |
| Q39755223 | Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions |
| Q40275257 | Hepatitis C virus E2 links soluble human CD81 and SR-B1 protein |
| Q36946317 | Hepatitis C virus entry |
| Q36581588 | Hepatitis C virus entry: molecular biology and clinical implications |
| Q34016463 | Hepatitis C virus entry: molecular mechanisms and targets for antiviral therapy |
| Q36749431 | Hepatitis C virus infection--pathobiology and implications for new therapeutic options |
| Q35196430 | Hepatitis C virus infection: when silence is deception. |
| Q34618241 | Hepatitis C virus molecular clones and their replication capacity in vivo and in cell culture |
| Q24563969 | Hepatitis C virus proteins |
| Q35704771 | Hepatitis C virus targets DC-SIGN and L-SIGN to escape lysosomal degradation |
| Q34974042 | Hepatitis C virus virology and new treatment targets |
| Q38332447 | High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I. |
| Q27481010 | High-Avidity Monoclonal Antibodies against the Human Scavenger Class B Type I Receptor Efficiently Block Hepatitis C Virus Infection in the Presence of High-Density Lipoprotein |
| Q42206367 | Human herpesvirus 8 glycoprotein B binds the entry receptor DC-SIGN. |
| Q27477468 | Identification of Conserved Residues in the E2 Envelope Glycoprotein of the Hepatitis C Virus That Are Critical for CD81 Binding |
| Q42996311 | Identification of glycosaminoglycan-binding sites within hepatitis C virus envelope glycoprotein E2*. |
| Q52654802 | Identification of serotonin 2A receptor as a novel HCV entry factor by a chemical biology strategy. |
| Q36967731 | Identification of transferrin receptor 1 as a hepatitis C virus entry factor |
| Q40488621 | Impact of polymorphisms in the DC-SIGNR neck domain on the interaction with pathogens |
| Q34605812 | Induction of hepatitis C virus-specific cytotoxic T and B cell responses by dendritic cells expressing a modified antigen targeting receptor |
| Q42706587 | Inhibition of predation by Bdellovibrio bacteriovorus and Micavibrio aeruginosavorus via host cell metabolic activity in the presence of carbohydrates |
| Q24676039 | Initiation of hepatitis C virus infection is dependent on cholesterol and cooperativity between CD81 and scavenger receptor B type I |
| Q42827093 | Interaction of L-SIGN with hepatitis C virus envelope protein E2 up-regulates Raf-MEK-ERK pathway |
| Q36242115 | Interactions between virus proteins and host cell membranes during the viral life cycle |
| Q34311548 | Interfering with hepatitis C virus RNA replication |
| Q42772176 | Interplay among cellular polarization, lipoprotein metabolism and hepatitis C virus entry. |
| Q36108089 | Is hepatitis C virus infection of dendritic cells a mechanism facilitating viral persistence? |
| Q37557428 | L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virus |
| Q110457422 | L-SIGN is a receptor on liver sinusoidal endothelial cells for SARS-CoV-2 virus |
| Q38323040 | LSECtin interacts with filovirus glycoproteins and the spike protein of SARS coronavirus |
| Q38596697 | Liver Sinusoidal Endothelial Cells |
| Q42997915 | Liver endothelial cells promote LDL-R expression and the uptake of HCV-like particles in primary rat and human hepatocytes. |
| Q34359990 | Liver immunology |
| Q37987860 | Living in the liver: hepatic infections |
| Q35669529 | Mechanisms of hepatitis C virus infection |
| Q33280966 | Micropatterning of living cells by laser-guided direct writing: application to fabrication of hepatic-endothelial sinusoid-like structures |
| Q40106501 | Mitogen-activated protein kinase signalling pathways triggered by the hepatitis C virus envelope protein E2: implications for the prevention of infection |
| Q27489898 | Mutagenesis of the fusion peptide-like domain of hepatitis C virus E1 glycoprotein: involvement in cell fusion and virus entry |
| Q35431256 | New Methods in Tissue Engineering: Improved Models for Viral Infection |
| Q36921336 | New therapeutic opportunities for hepatitis C based on small RNA. |
| Q35140337 | Nipah virus uses leukocytes for efficient dissemination within a host |
| Q29620681 | Novel insights into hepatitis C virus replication and persistence |
| Q40490998 | Nuclear receptors control pro-viral and antiviral metabolic responses to hepatitis C virus infection. |
| Q40334457 | Oligonucleotide-Lipid Conjugates Forming G-Quadruplex Structures Are Potent and Pangenotypic Hepatitis C Virus Entry Inhibitors In Vitro and Ex Vivo |
| Q37767654 | Potential of carbohydrate-binding agents as therapeutics against enveloped viruses |
| Q30333233 | Promising candidates for the treatment of chronic hepatitis C. |
| Q37489877 | Prospects of RNAi and microRNA-based therapies for hepatitis C. |
| Q38771712 | Protein Interactions during the Flavivirus and Hepacivirus Life Cycle |
| Q37945199 | Recent advances in hepatitis C virus cell entry |
| Q36956517 | Recent advances in our understanding of receptor binding, viral fusion and cell entry of hepatitis C virus: new targets for the design of antiviral agents |
| Q34280934 | Recurrent hepatitis C in liver allografts: prospective assessment of diagnostic accuracy, identification of pitfalls, and observations about pathogenesis |
| Q33753913 | Regulated Entry of Hepatitis C Virus into Hepatocytes |
| Q27481021 | Replication-Competent Recombinant Vesicular Stomatitis Virus Encoding Hepatitis C Virus Envelope Proteins |
| Q45421221 | Role of DC-SIGN in the activation of dendritic cells by HPV-16 L1 virus-like particle vaccine |
| Q27469844 | Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins |
| Q37887339 | Role of integrins in fibrosing liver diseases |
| Q27472767 | SOCS1 and SOCS3 are targeted by hepatitis C virus core/gC1qR ligation to inhibit T-cell function |
| Q24672232 | Scavenger receptor BI and BII expression levels modulate hepatitis C virus infectivity |
| Q27469468 | Scavenger receptor class B type I and hepatitis C virus infection of primary tupaia hepatocytes. |
| Q34657808 | Scavenger receptor class B type I mediates cell entry of hepatitis C virus |
| Q93005049 | Sexually transmitted hepatitis C virus infections: current trends, and recent advances in understanding the spread in men who have sex with men |
| Q57064243 | Structural Proteins of HCV and Biological Functions |
| Q38249917 | Targeting the C-type lectins-mediated host-pathogen interactions with dextran |
| Q28302262 | The C type lectins DC-SIGN and L-SIGN: receptors for viral glycoproteins |
| Q57265360 | The Structure of DC-SIGNR with a Portion of its Repeat Domain Lends Insights to Modeling of the Receptor Tetramer |
| Q38997186 | The allele 4 of neck region liver-lymph node-specific ICAM-3-grabbing integrin variant is associated with spontaneous clearance of hepatitis C virus and decrease of viral loads. |
| Q37962258 | The cell biology of receptor-mediated virus entry |
| Q34106742 | The heritage of pathogen pressures and ancient demography in the human innate-immunity CD209/CD209L region |
| Q27693297 | The impact of hepatitis C virus entry on viral tropism |
| Q37790420 | The multiple facets of HIV attachment to dendritic cell lectins |
| Q33517972 | The neck-region polymorphism of DC-SIGNR in peri-centenarian from Han Chinese population |
| Q28732733 | The origin and evolution of variable number tandem repeat of CLEC4M gene in the global human population |
| Q41586462 | The role of cellular adhesion molecules in virus attachment and entry |
| Q38301311 | The roles of direct recognition by animal lectins in antiviral immunity and viral pathogenesis. |
| Q38053123 | The scavenger endothelial cell: a new player in homeostasis and immunity |
| Q37952807 | The tug-of-war between dendritic cells and human chronic viruses |
| Q52624517 | Transmission of Turnip yellows virus by Myzus persicae Is Reduced by Feeding Aphids on Double-Stranded RNA Targeting the Ephrin Receptor Protein. |
| Q33896753 | Utilization of human DC-SIGN and L-SIGN for entry and infection of host cells by the New World arenavirus, Junín virus |
| Q30886599 | Viral hepatitis: new data on hepatitis C infection |
| Q37996242 | Virus entry: old viruses, new receptors |
| Q28588192 | Widely divergent biochemical properties of the complete set of mouse DC-SIGN-related proteins |
Search more.